The addition of topotecan (Hycamtin) to obrixtamig (BI … extensive-stage small cell lung cancer (ES-SCLC), according … AEs. “Obrixtamig plus topotecan was tolerable with no … obrixtamig plus topotecan in patients with advanced small cell lung cancer (SCLC …

… transforming the treatment landscape for lung cancer, offering new hope for patients … with both small cell lung cancer (SCLC) and non-SCLC ( … , which included lurbinectedin (Zepzelca; Jazz), topotecan (Hycamtin; Sandoz), and amrubicin (Calsed; Nippon …

… with relapsed small-cell lung cancer (SCLC) compared to … patients with small-cell lung cancer (SCLC) whose disease … small-cell lung cancer has been limited, with topotecan being the … in Relapsed Small Cell Lung Cancer (DeLLphi-304). ClinicalTrials.gov …

… lung cancer.2 Extensive-stage small cell lung cancer … lung cancer: a retrospective cohort study. Transl Lung Cancer Res … of lung cancer--what limits limited disease? Lung Cancer. 2002 … topotecan for second-line treatment of small cell lung cancer. Lung Cancer …

… 1 to either tarlatamab or topotecan, lurbinectedin, or amrubicin. … in Relapsed Small Cell Lung Cancer (DeLLphi-304). National … in Patients With Small Cell Lung Cancer (SCLC) (DeLLphi-301). … DLL3 in small cell lung cancer and other neuroendocrine carcinomas. …

… cytologically confirmed small cell lung cancer who experienced disease progression … chemotherapy comprising lurbinectedin (47 patients), topotecan (185 patients), or amrubicin … no), and intended chemotherapy (topotecan/amrubicin versus lurbinectedin). …

… immunotherapies for our patients with lung cancer.” Rudin is deputy director of … chemotherapy comprising lurbinectedin (n = 47), topotecan (n = 185), or amrubicin (n … vs no), and intended chemotherapy (topotecan/amrubicin vs lurbinectedin). OS …

… ’s position in small cell lung cancer with Jazz Pharmaceuticals’ Zepzelca has … -line extensive-stage small cell lung cancer (ES-SCLC) significantly reduced patients … the physician’s choice of topotecan or irinotecan. Jazz in-licensed …

… ;refractory advanced small cell lung cancer (SCLC), according to … obrixtamig, in combination] with topotecan, a well-known chemotherapeutic … [agent], which is topotecan. What makes obrixtamig’s … topotecan in patients (pts) with advanced small cell lung cancer …

… other approved options are topotecan and tarlatamab. If the … neoadjuvant non–small cell lung cancer [NSCLC] setting, particularly … extensive-stage-small-cell-lung-cancer Jazz Pharmaceuticals announces … extensive-stage small cell lung cancer. News release. Jazz …